ISB News

P4 Medicine: Antidote to Budget Woes?

Dr. Lee Hood, president of ISB, published an op-ed piece today on thehill.com’s Congress blog. His piece makes the case for P4 – personalized, predictive, preventive, participatory – medicine’s potential to shift medical care from disease-focused to wellness-focused, and thereby greatly reducing the cost of healthcare. You can read the post here.

LEARN MORE ABOUT ISB’S P4 MEDICINE:

healthcarefuture

The Puget Sound Business Journal featured P4 medicine in a special section on the “Health Care of the Future.” In this cover story, reporter Valerie Bauman explores the ramifications of personalized medicine from birth to death. Read the report: HealthCareFuture_PSBJ. Or explore ISB’s Web site section on P4.

 

Dr. Lee Hood’s TEDxRainier talk on P4 medicine:

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.